HRR

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
Lundi, avril 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)

Retrieved on: 
Mercredi, avril 17, 2024
HRD, Sophia Genetics, Laboratory, GENETICS, Machine learning, Artificial intelligence, NGS, HRR, DNA, Science, Patient, Neoplasm, Medicine, Ovarian cancer, FAMH

BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.

Key Points: 
  • Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.
  • Founded in 1987 in Switzerland, Unilabs conducts more than 221 million tests annually across its laboratories, imaging centers, and collection centers.
  • "SOPHiA GENETICS' AI-based technology is at the forefront of where precision medicine is going – blending science and technology to deliver the best possible outcomes for patients.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
Mercredi, mars 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Mercredi, février 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Mercredi, février 7, 2024
Sophia Genetics, GENETICS, DNA, Biomarker, Patient, Diagnosis, Laboratory, Corporate Affairs, AstraZeneca, HRR, Ovarian cancer, HRD, Cancer, NGS, Death, Health equity, Hospital, Pharmaceutical industry

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Lundi, janvier 8, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, European Commission, Food, HRR, Risk, Movement, Prognosis, PFE, Confidence interval, Disease, Prostate cancer, Doctor of Philosophy, Civil service commission, Cancer, University, PARP, Death, Clinical Cancer Research, University of Glasgow, ADP, Talazoparib, Patient, Safety, Medicine, Inc., Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
  • With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations.
  • “The European Commission’s approval of talazoparib in combination with enzalutamide offers a meaningful advancement for the treatment of patients with metastatic castration-resistant prostate cancer, the most advanced and aggressive stage of the disease.”
    “After years of fighting prostate cancer, it can be devastating for a patient to learn that their cancer has stopped responding to testosterone-lowering treatments.
  • At this stage of the disease, the prognosis is generally poor,” said Erik Briers, MS, PhD, Vice Chairman, Europa UOMO, a European advocacy movement for people with prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Mercredi, décembre 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Mercredi, décembre 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

SOPHiA GENETICS Expands Relationship with Città della Salute e della Scienza di Torino

Retrieved on: 
Mardi, novembre 28, 2023
BRCA1, Prostate, Data management, Breast, Research, HRR, Organization, Cancer, Hematology, DSM-IV codes, Patient, Medicine, Sophia Genetics, Intelligence, Machine learning, BRCA2, Partnership, Azure, Microsoft Azure, NGS, Biomarker, Microsoft, Health, GENETICS, Pharmaceutical industry, Medical device, Medical imaging

BOSTON and ROLLE, Switzerland, Nov. 28, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM™ Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 28, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy.
  • Città della Salute e della Scienza di Torino is part of one of the largest university hospitals and health systems in Europe.
  • The platform has enabled our researchers analyzing tumor samples to more quickly come to data-driven conclusions and move towards the practice of precision medicine," said Dr. Francia di Celle and Dr. Bonello, of the Molecular Pathology Laboratory, Città della Salute e della Scienza di Torino.
  • "The partnership between SOPHiA GENETICS and Microsoft provides clients such as Città della Salute e della Scienza di Torino with convenience and flexibility to implement the technology solutions necessary to suit their needs, while ensuring peace of mind that their data is secure," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS.

Integra Connect to Present Key Clinical Research at the ASCO Quality Care Symposium

Retrieved on: 
Mardi, octobre 24, 2023
NSCLC, American Society of Clinical Oncology, III, Biomarker, Water Quality Initiative, UPMC Hillman Cancer Center, Health, Research, AM, Society, Multimedia, Integra, Quality of life, PALM, Medicine, Histology, Abstract, HRR, Immunotherapy, Oncology, Lung cancer, Cancer, Patient, UPMC, ASCO, Nursing, Pharmaceutical industry, Stonemasonry, Medical imaging, MD

WEST PALM BEACH, Fla., Oct. 24, 2023 /PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023. The findings from these three studies – two done in conjunction with UPMC Hillman Cancer Center in Pittsburgh, PA and one done in conjunction with South Carolina Oncology Associates (SCOA) – emphasize the critical role quality initiatives play in identifying gaps in care and driving action to improve patient outcomes. Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.

Key Points: 
  • , the leading provider of value-based, precision medicine solutions and services for specialty care, today announced results from three studies that will be presented during the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium on October 27 - 28, 2023.
  • Findings for all three posters will be presented at ASCO Quality Care Symposium from 7:00 - 8:00 AM ET, and then again from 11:45 AM - 1:00 PM ET on October 28, 2023.
  • The studies were conducted with Integra Connect as part of its Quality Initiatives program, which is designed to help oncology practices, cancer institutes, and health systems make well-informed clinical decisions to ensure patients are receiving the best possible care.
  • Integra Connect does this by bringing together clinical data from disparate systems and sources, organizing the information into complete, longitudinal patient journeys, and conducting in-depth analyses with its AI-enabled solutions.